Ligand Pharmaceuticals: Owning It Gives You A Stake Across Biotech

Ligand Pharmaceuticals has declined approximately 10% since its prior Buy rating, prompting a reassessment of the investment case. The outlook remains constructive, centered on its royalty-producing assets and a high-growth business model that supports its positioning as a reliable midcap pharmaceutical company.